Surgery should only be offered to treat varicose veins if other less invasive treatments are unsuitable for patients, according to a guidance issued by the UK National Institute for Health and Care Excellence (NICE) on 24 July.
Thermocoagulation with a new endovenous radiofrequency system is a safe and efficient technique in the treatment of reflux of the great saphenous vein, according to a pilot study conducted in Belgium.
A comparative study performed to verify the new imagiQ2 low-dose table top from Stille has shown that the new device produces 20% lower radiation exposure than the previous model, imagiQ. The analysis was conducted at the Shoreline Surgical Associates Clinic, Middletown, USA, a clinic managed by vascular surgeon Joseph Coatti.
On 19 August 2013, Spectranetics announced the launch of the Turbo Elite 0.035 product line extension. The two new catheter sizes—with diameters of 2.3mm and 2.5mm—are compatible with a 0.035” guidewire, augmenting the versatility of the Turbo Elite laser to treat complex lesions including chronic total occlusions in blood vessels above and below the knee.
Avinger has received CE mark approval for Pantheris—a system that combines directional atherectomy capabilities with real-time intravascular visualisation to remove plaque from blocked arteries. Pantheris is designed to remove the blockage while avoiding the disruption of normal arterial wall structures. This new type of image-guided atherectomy is referred to as lumectomy.
A new mnemonic-based approach to aid the categorization of aortic dissection was developed by Michael D. Dake, MD, et al of the Working Group on Aortic Diseases of the DEFINE Project. The approach, called the DISSECT classification system, was published in the European Journal of Vascular & Endovascular Surgery (2013;46:175–190).
Biotronik, Inc. (Lake Oswego, OR) announced the launch of an extension of its lower limb portfolio. The company’s Passeo-35, which is a 0.035-inch over-the-wire (OTW) percutaneous transluminal angioplasty (PTA) balloon, is now available in additional lengths of up to 200 mm.
On 18 July 2013 Inovio announced that the use of its proprietary electroporation technology significantly enhanced the ability of a DNA therapy to stimulate blood vessel growth, which may be beneficial for the treatment of critical limb ischaemia and other forms of peripheral arterial disease.
Abbott announced on 21 August 2013 that it has completed its acquisition of IDEV Technologies, a privately held company focused on developing next-generation medical devices for use by interventional radiologists, vascular surgeons and interventional cardiologists.
One-year outcomes from the TriVascular Ovation global pivotal study were published in the Journal of Vascular Surgery on 26 August 2013. The paper concluded that “one-year outcomes with the Ovation stent graft are promising with excellent demonstrated safety and effectiveness in patients with abdominal aortic aneurysms. These results were similarly remarkable in patients with challenging anatomical characteristics who would be ineligible for treatment with other approved stent grafts.”
TriVascular announced on 17 July 2013 the initiation of a US Post-Approval Study (PAS) of the Ovation Prime Abdominal Stent Graft System for the treatment of abdominal aortic aneurysms. The study’s national principal investigator will be Syed Hussain, director of Vascular and Endovascular Surgery at OSF/HeartCare MidWest and assistant clinical professor of Surgery at University of Illinois College of Medicine in Peoria, USA.
On 27 August 2013, Lombard Medical announced that the first US patients have been successfully treated with Aorfix, the company’s flexible stent graft for the endovascular repair of abdominal aortic aneurysms.
Robert M. Bersin, MD, et al published results from the REFORM study in Catheterization and Cardiovascular Interventions (2013;82:266–273). REFORM is a prospective, single-arm, multicenter clinical study of the safety and effectiveness of the Formula balloon-expandable stent (Cook Medical, Bloomington, IN) for treating atherosclerotic renal artery stenosis (RAS) after suboptimal angioplasty.
AtheroMed, Inc. (Menlo Park, CA) announced that it has completed patient enrollment in the EASE clinical study, which is evaluating the company’s Phoenix atherectomy system in the treatment of peripheral arterial disease (PAD).
Boston Scientific has completed enrolment in the SuperNOVA trial, a global, single-arm, prospective, multicentre trial evaluating the long-term (12 month) safety and effectiveness of the Innova self-expanding stent system. This stent system is designed for treating patients with a narrowing or blockage of the arteries above the knee, often associated with peripheral arterial disease.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos